Abstract. Osteosarcoma is a highly malignant tumour that occurs in adolescents. Upregulation or the constitutive activation of epidermal growth factor receptor (EGFR) is a hallmark of osteosarcoma. To investigate the effect of ursolic acid on the biological function of osteosarcoma, MTT assay was used to detect the effect of ursolic acid on the proliferation of HOS and MG63 cells, while flow cytometry was used to analyse the effect on the cell cycle and apoptosis. Transwell and Matrigel assays were used to detect the effect of ursolic acid on cell migration and invasion, respectively. Western blot analysis and reverse transcription-quantitative polymerase chain reaction were used to detect the effects of different concentrations of ursolic acid on EGFR signaling pathway-related proteins, cell cycle, apoptosis and cell migration-related proteins. After overexpression or silencing of EGFR, the effects of ursolic acid on EGFR pathway and cell biological function were subsequently detected, using the same methods. The present study identified that ursolic acid had inhibitory effects on the growth and metastatic ability of osteosarcoma cells by suppressing EGFR.
Introduction
Osteosarcoma is a malignant bone tumour with a higher incidence in adolescents (1) . Currently, the use of doxorubicin-based chemotherapeutics in combination with aggressive surgery remains the standard treatment for osteosarcoma (2) . The poor survival rate is associated with the numerous pathological features of osteosarcoma, including high invasiveness, recurrent therapeutic resistance and multiple gene aberrations (3) .
Among these, gene dysregulation is an important factor in the tumourigenesis and progression of osteosarcoma (4) .
Epidermal growth factor receptor (EGFR) is highly expressed in lung cancer, osteosarcoma, ovarian and a variety of other tumours and is involved in their development (2) . Upregulation or the constitutive activation of EGFR is associated with tumourigenesis and more aggressive phenotypes in osteosarcoma (3, 5, 6) . Certain important signalling pathways in tumour cells, including PI3K/Akt, Wnt/β-catenin and mitogen-activated protein kinase (MAPK), are activated by EGFR. Anti-EGFR is considered an effective therapeutic target against osteosarcoma (5) .
Ursolic acid in its free form or in the form of a sugar glucoside can be found in ~7 families, 46 genera and 62 species of plants. A previous study has demonstrated that ursolic acid has a variety of pharmacological effects, including anti-inflammatory and immunosuppressant activities, and preventative effects against cartilage destruction (7) . Moreover, ursolic acid has been safely used in the treatment of arthritis for various years (8) . It has been reported that ursolic acid possesses anti-tumour effects and can regulate cell growth (9) . Ursolic acid has many biological functions (10) , can lower the blood pressure and presents anticancer properties (11) . Additionally, ursolic acid may inhibit the growth of cells, promote the apoptosis of tumour cells and mediate the invasion and metastasis of tumour cells (7) . However, there are few studies investigating the regulation of osteosarcoma by ursolic acid (12) .
The present study suggested that ursolic acid could effectively suppress the growth and metastasis of HOS cells by decreasing the expression level and the activity of EGFR. Importantly, ursolic acid may be an effective drug in the treatment of osteosarcoma. Transwell assay. The assays were performed using Transwell chambers, with or without Matrigel. A total of 1x10 5 HOS or MG63 cells treated with DMSO, 10, 20 or 30 µmol/l ursolic acid for 24 h were cultivated on the upper chamber with DMEM, and DMEM containing 10% bovine serum was added to the lower chamber. After 24 h incubation in a humidified incubator at 37˚C with 5% CO 2 , the medium was removed from the upper chamber. The non-invaded cells on the upper side of the chamber were scraped off with a cotton swab. The cells that had migrated into the pores of the inserted filter were stained with trypan blue for 20 min at room temperature. The numbers of cells were counted in three randomly selected visual fields, from the central and peripheral portion of the filter using an inverted microscope (x200 magnification; Leica DM2500M; Leica Microsystems GmbH). Each assay was repeated three times.
Materials and methods

Cell
Cell apoptosis. Apoptosis of HOS cells treated with DMSO, 10, 20 or 30 µmol/l ursolic acid for 24 h was detected with an Annexin-V-FITC apoptosis detection kit (Hanbio Biotechnology Co., Ltd.). In brief, cells were washed twice with cold PBS and suspended with binding buffer. Cells were incubated with 5 µl Annexin-V-FITC and 10 µl propidium iodide in the dark at room temperature for 15 min. Finally, binding buffer was added to each tube and the rate of apoptosis was measured using a flow cytometer within 1 h. Cells analysed using a MoFlo XDP flow cytometer (Beckman Coulter, Inc.). The analysis of data was using FlowJo software v10.0.7.2 (FlowJo LLC).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted with TRIzol ® (Invitrogen; Thermo Fisher Scientific, Inc.) from HOS or MG63 cells. A transcription kit (Beyotime Institute of Biotechnology,) was used for the RT of RNA into cDNA using the following conditions: 37˚C for 15 min and 85˚C for 5 sec. RT-qPCR was subsequently performed using a SYBR ® Green Real-time PCR master mix (Toyobo Life Science,). RT-qPCR was performed using MX3000P real-time PCR instrument according to the manufacturer's protocol (Beyotime Institute of Biotechnology), using the following conditions: 94˚C for 5 min, then 30 cycles of 94˚C for 30 sec, 58˚C for 30 sec, and elongation at 72˚C for 10 sec. β-actin was used as the internal control. The expression of miRNAs was detected using a miRcute miRNA qPCR detection kit (SYBR Green; Tiangen Biotech Co., Ltd.) (13) . Primer sequences are as follows: EGFR forward, 5'-CTA AGA TCC CGT CCA TCG CC-3' and reverse, 5'-GGA GCC CAG CAC TTT GAT CT-3'; cyclin D1 forward, 5'-GAT CAA GTG TGA CCC GGA C-3' and reverse, 5'-AGA GAT GGA AGG GGG AAA GA-3'; CDK4 forward, 5'-GCG TGA GGG TCT CCC TTG AT-3' and reverse, 5'-CAG TCG CCT CAG TAA AGC CA-3'; CDK6 forward, 5'-TCC CCA GAG TCT GAT TAC CT-3' and reverse, 5'-ACG ATT ACA TAG CCT CTG CC-3'; caspase 3 forward, 5'-ATG GAG AAC AAT AAA ACC T-3' and reverse, 5'-CTA GTG ATA AAA GTA GAG TTC-3'; Bcl-2 forward, 5'-CGA CGA CTT CTC CCG CCG CTA CC-3' and reverse, 5'-CCG CAT GCT GGG GCC GTA CAG-3'; Bax forward, 5'-TCC ACC AAG AAG CTG AGC GAG-3' and reverse, 5'-GTC CAG CCC ATG ATG GTT C-3'; matrix metallopeptidase 2 (MMP2) forward, 5'-CTA TTC TGC CAG CAC TTT GG-3' and reverse, 5'-CAG ACT TTG GTT CTC CAA C-3'; β-actin forward, 5'-GAG AGG GAA ATC GTG CGT GAC-3' and reverse, 5'-CAT CTG CTG GAA GGT GGA C-3' .
There were at least three replicates for each reaction. β-actin was used as the internal control.
Transfection. To silence EGFR, a set of synthesized small interfering (si)-RNAs against human EGFR (forward, 5'-CCU UAG CAG UCU UAU CUA ATD T-3' and reverse, 5'-TGG AAU CGU CAG AAU AGA UU-3'; Shanghai GeneChem Co., Ltd.) was used. HOS cells were transfected with pRS-siEGFR (forward, 5'-UUC UCC GAA CGU GUC ACG U-3' and reverse, 5'-ACG UGA CAC GUU CGG AGA A-3'; Shanghai GeneChem Co., Ltd.), using Lipofectamine 2000 ® (Invitrogen; Thermo Fisher Scientific, Inc.) and then selected with puromycin (Sigma-Aldrich; Merck KGaA). Cells transfected with pRS-si-NC (negative control) and wild type tumour cell lines were used as the control groups. For EGFR overexpression, EGFR (NCBI accession no. NM_201283.1) was amplified using PCR with the following primers: Forward, 5'-GAT CTG CAG GGG TTA GCT TGG GGA CCT GAA C-3' and reverse, 5'-GAT CAT ATG AGA GTG ACA TAC TGA TGC CT AC-3'. Subsequently 2 µg EGFR was cloned into pcDNA3.1 vector then transfected into HOS cells using Lipofectamine 2000 ® (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. A total of 2 µg pcDNA3.1 vector (Shanghai GeneChem Co., Ltd.) was used as the control. All primers were purchased from Shanghai GeneChem Co., Ltd.. After transfection for 24 h, cells treated with DMSO or 20 µmol/l of ursolic acid and MTT, Transwell and western blot experiments were performed.
Western blot analysis. HOS and MG63 cells (~1x10 5 ) were lysed with ice-cold lysis buffer containing NP40 buffer and a proteinase inhibitor cocktail (Invitrogen; Thermo Fisher Scientific, Inc.). The lysates were sonicated with an oscillation frequency of 15-25 KHz, at 4˚C for 10 sec, followed by centrifugation at 12,000 x g for 10 min at 4˚C and the supernatants were retained. Total protein concentration was quantified using a bicinchoninic acid protein assay kit (Applygen Technologies, Inc.), and western blot analysis was performed. A total of 30 µg protein/lane were resolved using 10% SDS-PAGE and transferred onto polyvinylidene fluoride membranes (Thermo Fisher Scientific, Inc.). Following blocking with 3% BSA (Beijing Solarbio Science & Technology Co., Ltd.) in TBS containing 0.1% Tween-20 for 3 h at room temperature, the membranes were incubated overnight at 4˚C with primary antibodies against EGFR (sc-80543; dilution 1:1,000), Akt1 (sc-135829; dilution 1:1,000), phosphorylated (p)-Akt1
Ser473 (sc-293125; dilution 1:1,000), β-actin (sc-69879; dilution 1:1,000), cyclin D1 (sc-4074; dilution 1:1,000), CDK4 (sc-70831; dilution 1:1,000), CDK6 (sc-271364; dilution 1:1,000), caspase-3 (sc-7272; dilution 1:1,000), Bax (sc-70407; dilution 1:1,000), Bcl-2 (sc-23960; dilution 1:1,000), MMP-2 (sc-13595; dilution 1:1,000). After several washes, the membranes were incubated with an appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies, mouse IgG-HRP (sc-2748; dilution 1:5,000) and rat IgG-HRP (sc-2750; dilution 1:5,000) for 1 h at room temperature. All antibodies brought from Santa Cruz Biotechnology, Inc.. The protein bands were visualized using enhanced chemiluminescence kits (GE Healthcare), and the optical density of the protein bands was quantified using the ImageJ v1.8.0 software (National Institutes of Health), using β-actin as an internal control.
Statistical analysis. All data were analysed using SPSS version 17.0 (SPSS, Inc.). Statistical significance between two groups of data was evaluated using two-tailed Student's t-test and one-way ANOVA. For multiple comparisons one-way ANOVA was used followed by LSD post hoc test. P<0.05 was considered to indicate a statistically significant difference. All experiments were repeated three times. Data are presented as the mean ± SD.
Results
Ursolic acid inhibits the growth and invasion of HOS cells.
The chemical structure of ursolic acid is shown in Fig. 1A . The MTT assay suggested that ursolic acid inhibited the proliferation of HOS cells in a concentration-dependent manner; through the calculation method of predecessors (14) , the IC 50 of ursolic acid was ~35 µmol/l (Fig. 1B and C) . Ursolic acid affected the proliferation of cells following treatment for 24 h, at which time the cell proliferation of the 10, 20 and 30 µmol/l ursolic acid treatment groups was significantly different compared to that of control group, P<0.05; therefore, this time point was used for subsequent experiments. In addition, ursolic acid inhibited the proliferation of MG63 cells; the IC 50 of ursolic acid was ~37 µmol/l ( Fig. 1D and E) . Cell cycle analysis was performed after HOS cells were exposed to ursolic acid for 24 h. 10, 20 and 30 µmol/l ursolic acid arrested HOS cells at the G 1 phase of the cell cycle (Fig. 1F) . Furthermore, Annexin-V-FITC staining demonstrated that 10, 20 and 30 µmol/l ursolic acid could induce cell apoptosis (Fig. 1G) . Ursolic acid also significantly decreased the cell migration and invasion of HOS and MG63 cells (Fig. 1H-K ) without affecting the expression of Akt, an important protein in the EGFR signalling pathway (Fig. 2A) . Therefore, we hypothesized that ursolic acid may regulate the EGFR signalling pathway. Compared with the DMSO group, there were no statistically significant differences in the mRNA level of EGFR in the 10 and 20 µmol/l ursolic acid groups; however, 30 µmol/l ursolic acid significantly reduced EGFR mRNA expression (Fig. 2B) . The present results suggested that, at low concentrations, ursolic acid only affected the expression of EGFR protein and had little effect on mRNA expression, although higher doses may affect the synthesis of mRNA. When the concentration was increased to 30 µmol/l, ursolic acid inhibited EGFR expression at the protein and mRNA levels.
Since the biological function of osteosarcoma cells has been significantly affected by ursolic acid at 20 µmol/l for 24 h, this concentration and time point was used for the further experiments. To further verify the inhibitory effect of ursolic acid on EGFR, an EGFR overexpression plasmid was transfected into HOS cells (Fig. 2C and D) , which were then treated with or without 20 µmol/l ursolic acid for 24 h (Fig. 2E ). The present results suggested that ursolic acid decreased the level of EGFR and p-Akt (Ser 473 ) in the vector and EGFR overexpression groups (Fig. 2E) . The HOS/si-EGFR stable cell line was then used to detect the effect of ursolic acid on EGFR (Fig. 2F-H) . Ursolic acid inhibited the p-Akt of EGFR overexpression group more strongly compared to that in the vector group (Fig. 2G) . It also inhibited the p-Akt of NC group more strongly compared with that in the si-EGFR group (Fig. 2H) . Ursolic acid treatment downregulated EGFR and p-Akt (Ser 473 ) significantly in HOS/si-NC stable cell lines. The effect of ursolic acid was reduced after EGFR silencing in cells. Therefore, it was concluded that ursolic acid might inhibit proteins in the downstream signaling pathway by inhibiting EGFR.
Ursolic acid inhibits the growth of HOS cells.
Western blot analysis suggested that increasing concentrations of ursolic acid significantly decreased the protein expression level of cyclin D1, CDK4 and CDK6 (Fig. 3A) . Furthermore, cyclin D1, CDK4 and CDK6 in HOS cells were also significantly downregulated at the mRNA level following treatment with increasing concentrations of ursolic acid (Fig. 3B) . Apoptosis factors were investigated, and the present results suggested that Bcl-2 was significantly downregulated and caspase 3 and Bax were significantly upregulated at both the protein and mRNA levels ( Fig. 3C and D) .
The MTT assay showed that the proliferation of cells overexpressing EGFR was significantly inhibited by ursolic acid (Fig. 4A) . Results from the HOS/si-EGFR cells suggested that there were significant decrease in the extent of proliferation inhibition between HOS/si-NC and HOS/si-EGFR cell lines (Fig. 4B) .
Cell growth and apoptosis-related regulators were also detected in cells following overexpression or knockdown of EGFR, and after treatment with ursolic acid. Overexpression of EGFR induced the protein expression levels of cyclin D1, CDK4, CDK6 and Bcl-2 compared with that in the vector group. Moreover, the inhibitory effect of ursolic acid on cyclin D1, CDK4, CDK6 and Bcl-2 in EGFR overexpressed cells was greater compared with that of ursolic acid on the same proteins in the vector group (Fig. 4C and D) . However, after knockdown of EGFR, the changes in these proteins were markedly reduced ( Fig. 4E and F) . By contrast, Bax and caspase 3 decreased following EGFR overexpression and decreased following EGFR knockdown.
Ursolic acid represses the metastasis of HOS.
Osteosarcoma is typically advanced due to its high invasiveness (15) . MMP2 is an important protein regulating cell migration and a functional protein downstream of EGFR (16) . Therefore, the regulatory effect of ursolic acid on MMP2 was investigated. The present results suggested that the expression of MMP2 was significantly decreased at increasing concentrations of ursolic acid (Fig. 5A and B) . To investigate the involvement of EGFR in the ursolic acid-dependent inhibition of cell invasion and migration (Fig. 1H-K) , a Transwell assay was performed ( Fig. 5C-F) . EGFR could promote the migration of HOS cells, whereas ursolic acid could significantly reduce the migratory ability of HOS cells. After the inhibition of EGFR, the effect of ursolic acid was reduced. In the HOS cell lines, the protein expression level of MMP2 decreased following treatment with ursolic acid (Fig. 5G and H) .
Discussion
EGFR can regulate cellular processes via kinase-independent and -dependent signalling pathways. EGFR mutants with no kinase activity, such as EGFR (D813A) and EGFR (K721M), can induce activation of MAPK and activate survival signals by interacting with other important proteins, such as receptor tyrosine-protein kinase (17) . In the EGFR kinase-dependent signalling pathway, the phosphorylation of EGFR induces the activation of a number of pathways, including MAPK/ERK, phosphoinositide phospholipase Cγ/protein kinase C/NF-κB, SRC proto-oncogene, non-receptor tyrosine kinase, PI3K and STAT3, which are associated with cell proliferation, apoptosis, cell cycle regulation and DNA damage repair (18) . Due to the important role of EGFR, this receptor is one of the most promising therapeutic targets (6) .
Ursolic acid has previously been used for the treatment of rheumatoid arthritis (19) . In recent years, antitumour effects of ursolic acid have been found in synovial sarcoma, lung cancer, endometrial cancer cells and hepatocellular carcinoma (11, (20) (21) (22) (23) .
In many types of cancer, including osteosarcoma, overexpression of EGFR is associated with aggressive invasiveness and resistance to therapy (24) (25) (26) . Previous studies have indicated that EGFR may be an effective target for the treatment of human cancer (27, 28) . The US Food and Drug Administration has approved five anti-EGFR agents for cancer treatment including three small molecule inhibitors and two antibodies (29) . The present study revealed that ursolic acid had inhibitory effects on the growth and metastatic ability of HOS cells in a concentration-dependent manner. Notably, ursolic acid could significantly inhibit the expression of EGFR.
Thus, ursolic acid could be considered as a natural inhibitor of EGFR, and its antitumour effect may be partly due to the inhibition of EGFR, as EGFR can regulate various biological functions such as cell growth and metastasis (3). Therefore, it was identified that ursolic acid can inhibit EGFR, and the biological effect of ursolic acid was further investigated. The present study also suggested that ursolic acid could inhibit the cell cycle G 1 -to-S transition by inhibiting the expression of cyclin D1 and CDK4 and CDK6. This inhibition in cell cycle may be caused by the inhibitory effect of ursolic acid on EGFR. Furthermore, ursolic acid not only affected the proliferation of cells, but also inhibited the invasion and metastasis of cells; this inhibitory effect of ursolic acid on cell metastasis may involve the inhibition of MMP2.
In conclusion, the present study demonstrated that ursolic acid could inhibit the malignant phenotype of HOS cells by inhibiting EGFR expression and EGFR-associated signalling pathways. Although these results require further investigaton in vivo, the present findings support the hypothesis that ursolic acid may facilitate the development of a novel clinical treatment of osteosarcoma.
